• Positive new azer-cel data: 6 total Complete Responses and 3 Partial Reponses (75% Overall Response Rate) in Phase 1b trial
• Clearance of first dose level in the intravenous (IV) combination arm of OASIS Phase 1 onCARlytics clinical trial
• First patient dosed in Australia for PD1-Vaxx Neo-POLEM Phase II trial

Imugene Limited, a clinical-stage immuno-oncology company, has announced its Quarterly Cash Flow report for the quarter ended 30 June 2025. The report highlights positive clinical updates, including further encouraging results from the Phase 1b trial of azer-cel, an allogeneic 'off-the-shelf' CD19-targeting CAR T therapy for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Since the last update, five additional patients have been treated, with two achieving complete responses and three achieving partial responses, bringing the trial's total best response rate to 75%. The company also reported clearance of the first dose level in the intravenous (IV) combination arm of its Phase 1 onCARlytics clinical trial, known as OASIS, and the dosing of the first patient in Australia as part of the PD1-Vaxx Neo-POLEM Phase II trial. On the corporate front, the company announced the promotion of Dr John Byon to Chief Medical Officer, and completed a $22.5 million institutional placement, with a $15 million Share Purchase Plan pending. The company also received a $5.8 million R&D tax refund for the 2024 financial year.

The company anticipates that the funding from the institutional placement, Share Purchase Plan, and R&D tax refund, together with potential future proceeds from the exercising of options, will extend its cash runway into the 2027 calendar year.